Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular Testingpriority health cellular gene therapy Prior Auth |…
    Ask Trek AI about this page
    Currentpriority healthPolicy NO. 91638

    CELLULAR AND GENE THERAPY

    Customize your policy alerts

    Sign up for priority health Policy NO. 91638 alerts

    Get alerted when Policy NO. 91638 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Prior Authorization, provider, facility, coding, and coverage considerations for cellular and gene therapy products (including CAR-T) and applies to Priority Health members according to their benefit plans.

    Policy Summary
    Payerpriority health
    PolicyCELLULAR AND GENE THERAPY
    Policy CodePolicy NO. 91638
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Last ReviewMay 13, 2026
    Next Review DateMay 13, 2026
    Key ActionObtain prior authorization demonstrating medical necessity before administering cellular or gene therapy.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Prior authorization requiredauthorization requirement
    FDA-aligned dosing

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    use requirement
    087X, 089Xrevenue codes
    38225-38228procedure codes

    Coverage Criteria and Eligibility

    General medical necessity criteria

    Covered when ALL of the following are met

    General requirements: 1) Prior authorization has been obtained as required by Priority Health; 2) Treatment limits are met — cellular and gene therapy products have clinically appropriate limits for treatment and repeat administrations beyond a single lifetime treatment are generally not evaluated; 3) Dosing and administration are strictly aligned with the FDA‑approved indication (requests for off‑label dosing or use will not be approved); 4) Coverage is consistent with the member's specific benefit plan and any applicable group‑specific policy; 5) The provider and facility administering the treatment are participating (in‑network) and meet Priority Health's reimbursement and facility/provider requirements.

    Coverage determinations follow product‑specific criteria listed on Priority Health's Approved Drug List (see medical benefit drug information).

    Use of cellular and gene therapy products (including CAR-T) for indications consistent with FDA approvals and product-specific criteria as listed on Priority Health's Approved Drug List.

    FDA‑aligned and product‑specific coverage: Use of cellular and gene therapy products (including CAR‑T) is covered when the indication, dosing, and administration are consistent with the FDA‑approved labeling and when the product meets Priority Health's product‑specific coverage criteria as listed on the Approved Drug List.

    Prior authorization is required; coverage determinations reference the Approved Drug List and product‑specific criteria.

    Requests for off-label dosing or use of cellular and gene therapy products, including CAR‑T therapies, will not be approved. This aligns with the policy requirement that dosing and administration must be strictly aligned with the FDA‑approved indication and that off‑label requests are excluded from coverage.

    Coverage for experimental, investigational, or unproven treatments is excluded except when an individual case review is requested and prior plan approval is obtained. Such requests for exception are reviewed by a Priority Health medical director or clinical pharmacist and may be considered only for conditions that are terminal or causing serious clinical deterioration.

    Billing and Code Guidance

    Relevant revenue codesRevenue
    087XCell/Gene Therapy (includes 0870, 0871, 0872, 0873, 0874, 0875)
    089XPharmacy - (Extension of 025X and 063X) (includes 0890, 0891, 0892)
    CPT/HCPCS CodesCPT
    38225Chimeric antigen receptor T-cell (CAR-T) therapy; harvesting of blood-derived T lymphocytes for development of genetically modified autologous CAR-T cells, per day.
    38226Chimeric antigen receptor T-cell (CAR-T) therapy; preparation of blood-derived T lymphocytes for transportation (eg, cryopreservation, storage).
    38227Chimeric antigen receptor T-cell (CAR-T) therapy; receipt and preparation of CAR-T cells for administration.
    38228Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous.

    Provider Requirements and Authorization

    Prior Authorization

    Prior Authorization Required

    Prior Authorization is required for cellular and gene therapy products. Coverage determinations follow product-specific criteria listed on Priority Health's Approved Drug List page. Providers must submit a prior authorization request prior to administration.

    • Affected products: cellular and gene therapy products, including CAR T-cell therapies
    • Prior authorization must be obtained before treatment
    • Coverage determinations follow product-specific criteria on Priority Health's website
    Documentation Required

    Medical Necessity Documentation

    Providers must document and submit evidence demonstrating medical necessity when requesting prior authorization. Individual case review may permit coverage of investigational or unproven treatments in limited circumstances (e.g., terminal illness or chronic, life‑threatening, severely disabling disease causing serious clinical deterioration); such requests require prior plan approval and review by a Priority Health medical director or clinical pharmacist.

    Exclusions and Non-Covered Items

    Off‑label dosing or use and investigational/unproven treatments are not covered under this policy except when an individual case review is performed and prior plan approval is granted. Individual exceptions are evaluated by Priority Health clinical leadership and are limited to cases meeting the policy's criteria for review (for example, terminal illness or severe clinical deterioration).

    Background

    Cellular, gene, and chimeric antigen receptor T‑cell (CAR‑T) therapies use living cells or genetic material to treat disease. CAR‑T therapy involves collection of a patient’s T cells, ex vivo genetic modification to express a chimeric antigen receptor, and reinfusion to target malignant cells. These therapies are primarily used for certain hematologic malignancies and require specialized administration, monitoring, and facility/provider participation to meet safety and reimbursement requirements.

    Definitions

    CAR-T therapy — definition and process summary
    Process summaryCollection of patient T cells, ex vivo genetic modification to express a CAR, expansion/preparation of modified cells, and reinfusion (administration) back to the patient.
    Cell originTypically autologous (patient-derived) T cells are used; involves ex vivo manipulation before return to the patient.
    Clinical usePrimarily used for certain hematologic malignancies and associated with unique administration, monitoring, and toxicity-management needs.
    Relation to other therapiesIncorporates elements of both cell therapy and gene therapy (genetic modification of cells) and is distinct from hematopoietic stem cell or bone marrow transplantation.
    Gene therapy — definition and scope summary
    Definition
    Policy Summary
    Payerpriority health
    PolicyCELLULAR AND GENE THERAPY
    Policy CodePolicy NO. 91638
    Change TypeNo material changes
    Effective DateJun 1, 2026
    Last ReviewMay 13, 2026
    Next Review DateMay 13, 2026
    Key ActionObtain prior authorization demonstrating medical necessity before administering cellular or gene therapy.
    SourceLink
    On This Page
    Coverage Criteria and EligibilityBilling and Code GuidanceProvider Requirements and AuthorizationExclusions and Non-Covered ItemsBackgroundDefinitions
    • Include clinical justification, relevant diagnostics, prior therapies, and treatment intent
    • Requests for individual consideration require prior plan approval
    • All determinations for experimental/investigational treatments are made by a Priority Health medical director or clinical pharmacist
    Denial Risk

    Treatment Limits and FDA‑Aligned Dosing

    Clinical limits apply to cellular and gene therapy products; many products have only a single lifetime administration evaluated and repeat administrations are generally not approved. Dosing and administration must match FDA‑approved indications; requests for off‑label dosing or use will not be approved. Coverage is subject to the member's benefit plan.

    • Repeat administrations beyond a single lifetime treatment are generally not evaluated
    • Dosing must align with FDA‑approved indication — off‑label dosing/use will not be approved
    • Coverage subject to member's benefit plan documents
    Billing Rule

    Provider and Facility Requirements

    The provider and facility administering cellular and gene therapy must be participating (in‑network) and comply with Priority Health's reimbursement requirements for outpatient medical drugs (Billing Policy No. 092). Referrals should be to in‑network or contracted facilities. See Priority Health medical benefit drug information page for additional instructions.

    • Ensure provider and facility are in‑network and meet Reimbursement Requirements (Outpatient Medical Drugs Billing Policy No. 092)
    • Refer members to Priority Health network or contracted facilities
    • Consult Priority Health medical benefit drug information page for details
    Gene therapy: techniques that modify or manipulate gene expression or alter biological properties of living cells to treat disease, including replacing, inactivating/silencing, or introducing genes.
    MechanismsMay work by replacing a disease-causing gene with a functional copy, inactivating or silencing a malfunctioning gene, or introducing a new or modified gene into the body.
    Product typesIncludes plasmid DNA therapies, viral vector–based therapies, bacterial vector–based therapies, human gene-editing technologies, and patient-derived cellular gene therapy products.
    Patient-derived approachPatient-derived cellular gene therapy: cells are collected from the patient, genetically modified (often using a viral vector), and returned to the patient for therapeutic effect.
    Clinical applicationsBeing studied and applied for conditions such as cancer, inherited genetic disorders, and select infectious diseases.